These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 19269165)

  • 21. Potential of intermittent hormone therapy for M+ and M0 prostate cancer patients.
    Oliver RT; Farrugia D; Ansell W; Williams G; Chinegwundoh F
    Prostate Cancer Prostatic Dis; 2000 Dec; 3(4):286-289. PubMed ID: 12497080
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Endocrine approaches in the therapy of prostate carcinoma.
    d'Ancona FC; Debruyne FM
    Hum Reprod Update; 2005; 11(3):309-17. PubMed ID: 15790600
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Maximal androgen blockade for advanced prostate cancer.
    Klotz L
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):331-40. PubMed ID: 18471790
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current status and prospects of androgen depletion therapy for prostate cancer.
    Akaza H
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):293-302. PubMed ID: 18471787
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intermittent chemotherapy for metastatic hormone refractory prostate cancer.
    Lin AM; Ryan CJ; Small EJ
    Crit Rev Oncol Hematol; 2007 Mar; 61(3):243-54. PubMed ID: 17161610
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a European perspective.
    Boccon-Gibod L
    BJU Int; 2007 Jan; 99 Suppl 1():2-5; discussion 17-8. PubMed ID: 17229159
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current status of endocrine therapy for prostate cancer in Japan analysis of primary androgen deprivation therapy on the basis of data collected by J-CaP.
    Hinotsu S; Akaza H; Usami M; Ogawa O; Kagawa S; Kitamura T; Tsukamoto T; Naito S; Namiki M; Hirao Y; Murai M; Yamanaka H;
    Jpn J Clin Oncol; 2007 Oct; 37(10):775-81. PubMed ID: 17965423
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [A way of thinking of a MAB therapy for local/locally advanced prostate cancer: the theory and recent evaluation].
    Akaza H; Labrie F; Namiki M
    Gan To Kagaku Ryoho; 2007 Apr; 34(4):657-69. PubMed ID: 17431361
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design.
    Sartor O; Gomella LG; Gagnier P; Melich K; Dann R
    Can J Urol; 2009 Oct; 16(5):4806-12. PubMed ID: 19796455
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnostic evaluation of PSA recurrence and review of hormonal management after radical prostatectomy.
    Van Poppel H; Joniau S; Van Cleynenbreugel B; Mottaghy FM; Oyen R
    Prostate Cancer Prostatic Dis; 2009; 12(2):116-23. PubMed ID: 19238169
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase II study investigating the re-induction of endocrine sensitivity following chemotherapy in androgen-independent prostate cancer.
    Shamash J; Davies A; Ansell W; Mcfaul S; Wilson P; Oliver T; Powles T
    Br J Cancer; 2008 Jan; 98(1):22-4. PubMed ID: 18182976
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The study landscape for prostate cancer].
    Miller K
    Urologe A; 2005 Dec; 44(12):1431-4. PubMed ID: 16292461
    [TBL] [Abstract][Full Text] [Related]  

  • 33. American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer.
    Loblaw DA; Mendelson DS; Talcott JA; Virgo KS; Somerfield MR; Ben-Josef E; Middleton R; Porterfield H; Sharp SA; Smith TJ; Taplin ME; Vogelzang NJ; Wade JL; Bennett CL; Scher HI;
    J Clin Oncol; 2004 Jul; 22(14):2927-41. PubMed ID: 15184404
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [A new LH-RH agonist for treatment of prostate cancer, 3-month controlled-release formulation of goserelin acetate (Zoladex LA 10.8 mg depot)--outline of pre-clinical and clinical studies].
    Tsukagoshi S
    Gan To Kagaku Ryoho; 2002 Sep; 29(9):1675-87. PubMed ID: 12355959
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Advances in the management of metastatic androgen-independent prostate cancer.
    Laber DA; Goetz H K; Bhupalam L
    J Ky Med Assoc; 2006 Feb; 104(2):65-9. PubMed ID: 16594572
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum testosterone recovery after cessation of long-term luteinizing hormone-releasing hormone agonist in patients with prostate cancer.
    Bong GW; Clarke HS; Hancock WC; Keane TE
    Urology; 2008 Jun; 71(6):1177-80. PubMed ID: 18279929
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The benefits of early androgen blockade.
    Maroni PD; Crawford ED
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):317-29. PubMed ID: 18471789
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Zibotentan for the treatment of castrate-resistant prostate cancer.
    Shepard DR; Dreicer R
    Expert Opin Investig Drugs; 2010 Jul; 19(7):899-908. PubMed ID: 20497097
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of systemic cytotoxic therapy for prostate cancer.
    Chang SS; Kibel AS
    BJU Int; 2009 Jan; 103(1):8-17. PubMed ID: 19040524
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A 10-year clinical experience with intermittent hormonal therapy for prostate cancer.
    Prapotnich D; Fizazi K; Escudier B; Mombet A; Cathala N; Vallancien G
    Eur Urol; 2003 Mar; 43(3):233-39; discussion 239-40. PubMed ID: 12600425
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.